[Literature Review of the Efficacy and Safety of Hyperthermic Intraperitoneal Perfusion Chemotherapy After Cytoreductive Surgery in the Treatment of Pseudomyxoma Peritonei]

Zhonghua Wei Chang Wai Ke Za Zhi. 2011 Feb;14(2):132-5.
[Article in Chinese]


Objective: To evaluated the safety and efficacy of hyperthermic intraperitoneal perfusion chemotherapy(HIPC) in the prevention and treatment of pseudomyxoma peritonei (PMP) recurrence after cytoreductive surgery(CRS).

Methods: Studies published in English before 2010 on HIPC after CRS for PMP were searched in PubMed database. Each study was carefully evaluated based on pre-determined criteria. Study results were comprehensively displayed in a form. A descriptive systematic review was performed.

Results: A total of 11 studies were included. The median survival time of patients in these studies ranged from 25.6 months to 156 months. The ranges of 1-year, 2-year, 3-year, 5-year, and 10-year survival rates were 72%-100%, 55%-96%, 59%-96%, 52%-96%, and 55%-96%, respectively. The overall complication rate ranged from 2%-15%, and the total perioperative mortality were from 0 to 7%.

Conclusion: HIPC after CRS is effective and safe for patients with PMP.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Chemotherapy, Cancer, Regional Perfusion / methods
  • Humans
  • Peritoneal Neoplasms / drug therapy*
  • Peritoneal Neoplasms / surgery
  • Postoperative Care
  • Pseudomyxoma Peritonei / drug therapy*
  • Pseudomyxoma Peritonei / surgery
  • Treatment Outcome